Date: 2016-12-05
Type of information: Financing round
Company: Ixchelsis (UK)
Investors: TVM Life Science VII (Canada) Pfizer Venture Investments (USA - NY)
Amount: $ 12 million
Funding type: financing round
Planned used: Ixchelsis is a start-up company based at Discovery Park, Sandwich, Kent, UK. This funding will enable Ixchelsis to fully fund its planned Phase 2b study of IX-01, an oral oxytocin receptor antagonist, in patients with severe lifelong premature ejaculation. In January 2016, the company had reported that it had achieved positive clinical proof of concept for IX-01 in patients with lifelong premature ejaculation. IX-01 demonstrated significant efficacy together with a very benign safety and toleration profile in patients suffering from the most severe lifelong form of premature ejaculation.
Others: * On December 5, 2016, Pfizer Venture Investments and TVM Life Science Ventures VII announced that they are making an additional $12M investment in Ixchelsis. Ixchelsis is the second investment for TVM Life Science Ventures VII, a venture capital fund domiciled in Montreal, which follows a new investment approach to developing pharmaceutical assets, in a capital efficient fashion in single asset companies.
Therapeutic area: Urological diseases
